← Back to Search

The EMC2 PrEP Strategy for Electronic Health Records

N/A
Recruiting
Led By Allison Pack, PhD, MPH
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
not currently using PrEP
female
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial is trying to find a way to help women in primary care learn more about and use a method called pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Who is the study for?
This trial is for cisgender women who are HIV negative, not currently using PrEP, and engaged in primary care. They must have been tested at least twice in the past year or diagnosed with certain STIs like chlamydia, gonorrhea, or syphilis within the last six months.Check my eligibility
What is being tested?
The study tests an educational tool called EMC2 PrEP to see if it helps increase knowledge and use of HIV prevention methods. It also looks at organizing a dedicated visit for discussing PrEP as part of this strategy.See study design
What are the potential side effects?
Since this trial focuses on education and scheduling strategies rather than medication, there are no direct side effects from interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not currently using PrEP.
Select...
I am female.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PrEP Uptake
Secondary outcome measures
PrEP Knowledge

Trial Design

2Treatment groups
Active Control
Group I: The EMC2 PrEP StrategyActive Control2 Interventions
The EMC2 PrEP Strategy will utilize health information and consumer technologies to automatically deposit an interactive PrEP educational material into the patient portal of women with clinically indicated increased vulnerability to HIV. The material will: 1) promote PrEP knowledge, and 2) prompt discrete scheduling of a dedicated PrEP visit among those interested.
Group II: Usual CareActive Control1 Intervention
Usual care includes: 1) no specific materials to promote PrEP knowledge or uptake among women in primary care, and 2) variable physician counseling on PrEP among women with increased vulnerability to HIV.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,589 Previous Clinical Trials
916,887 Total Patients Enrolled
1 Trials studying Electronic Health Records
840 Patients Enrolled for Electronic Health Records
Merck Sharp & Dohme LLCIndustry Sponsor
3,892 Previous Clinical Trials
5,060,946 Total Patients Enrolled
Allison Pack, PhD, MPHPrincipal InvestigatorNorthwestern University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being actively enrolled in this research study?

"Indeed, the current status of this trial on clinicaltrials.gov indicates that it is actively seeking participants. The trial was initially posted on November 29th, 2023 and last updated on December 18th, 2023. It aims to recruit a total of 200 patients from a single site."

Answered by AI

What is the current number of individuals actively involved in this clinical investigation?

"Indeed, according to the information available on clinicaltrials.gov, this ongoing clinical trial is actively seeking participants. The trial was initially posted on November 29th, 2023 and has recently been updated on December 18th, 2023. For enrollment purposes, they aim to recruit a total of 200 patients from a single location."

Answered by AI
~100 spots leftby Sep 2024